However, studies in patients with relapsed/refractory AML have shown only minor efficacy for the VEN/AZA combination [30], and Jones et al. have demonstrated that LSCs from patients with relapsed/refractory AML can escape loss of amino acid/(BCL-2)-dependent OXPHOS by increasing fatty acid metabolism-driven OXPHOS [11]. Here, BCL2 is linked to acute myeloid leukemia.